167 related articles for article (PubMed ID: 34076400)
21. Dermal sensitization, safety, tolerability, and patient preference of tazarotene 0.045% lotion from five clinical trials.
Kircik LH; Green L; Guenin E; Khalid W; Alexander B
J Dermatolog Treat; 2022 Jun; 33(4):2241-2249. PubMed ID: 34459694
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Tazarotene Lotion, 0.045% in the Treatment of Truncal Acne Vulgaris.
Kircik L
J Drugs Dermatol; 2022 Jul; 21(7):713-716. PubMed ID: 35816073
[TBL] [Abstract][Full Text] [Related]
23. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
[TBL] [Abstract][Full Text] [Related]
24. The Effects of Once-Daily Tretinoin 0.05% Lotion on Quality of Life in Patients with Moderate-to-Severe Acne Vulgaris.
Tyring SK; Kircik L; Pariser DM; Woolery-Lloyd HC; Harper JC; Bhatt V; Pillai R; Guenin E
Am J Clin Dermatol; 2020 Dec; 21(6):891-899. PubMed ID: 32886337
[TBL] [Abstract][Full Text] [Related]
25. Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females.
Stein Gold L; Elewski B; Draelos Z; Jacobson A; Lin T
J Drugs Dermatol; 2020 May; 19(5):504-514. PubMed ID: 32484629
[TBL] [Abstract][Full Text] [Related]
26. Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials.
Shalita AR; Berson DS; Thiboutot DM; Leyden JJ; Parizadeh D; Sefton J; Walker PS; Gibson JR;
Clin Ther; 2004 Nov; 26(11):1865-73. PubMed ID: 15639698
[TBL] [Abstract][Full Text] [Related]
27. Tazarotene 0.045% Lotion for Moderate-to-Severe Acne in Male and Female Participants: A Phase II
Baldwin HE; Green LJ; Kircik L; Guenin EP; Forest AL; Pillai R
J Clin Aesthet Dermatol; 2021 Apr; 14(4):E53-E60. PubMed ID: 34055190
[No Abstract] [Full Text] [Related]
28. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
Feldman SR; Werner CP; Alió Saenz AB
J Drugs Dermatol; 2013 Apr; 12(4):438-46. PubMed ID: 23652892
[TBL] [Abstract][Full Text] [Related]
29. Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne in Adult and Pediatric Participants.
Baldwin H; Gold LS; Harper JC; Alexis AF; Callender VD; Kircik L; Guenin E; Eichenfield LF
J Drugs Dermatol; 2024 Jun; 23(6):394-402. PubMed ID: 38834226
[TBL] [Abstract][Full Text] [Related]
30. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
[TBL] [Abstract][Full Text] [Related]
31. Tazarotene 0.045% Lotion: A Novel Retinoid Formulation.
Mohney LA; Singh R; Feldman SR
Ann Pharmacother; 2022 Oct; 56(10):1174-1180. PubMed ID: 35112585
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients.
Keri J; Cook-Bolden FE; Green L; Kircik LH; Baldwin H; Werschler WP; Guenin E; Pillai R; Bhatt V
J Dermatolog Treat; 2022 Sep; 33(6):2790-2799. PubMed ID: 35833564
[TBL] [Abstract][Full Text] [Related]
33. Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities.
Tyring S; Kircik LH; Yamauchi P; Jacobson A; Lin T
J Drugs Dermatol; 2020 Apr; 19(4):389-396. PubMed ID: 32272516
[TBL] [Abstract][Full Text] [Related]
34. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris.
Tanghetti E; Dhawan S; Green L; Ling M; Downie J; Germain MA; Kasteler JS; Kircik L; Oefelein MG; Draelos Z
J Drugs Dermatol; 2011 Jul; 10(7):783-92. PubMed ID: 21720661
[TBL] [Abstract][Full Text] [Related]
35. Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis.
Kircik LH; Papp KA; Stein Gold L; Harris S; Pharm TL; Pillai R
J Drugs Dermatol; 2019 Mar; 18(3):279-284.. PubMed ID: 30909333
[TBL] [Abstract][Full Text] [Related]
36. Influence of Season on Efficacy and Tolerability of Tazarotene 0.045% Lotion for the Treatment of Acne.
Tan J; Draelos ZD; Gooderham MJ; Alexis AF; Graber E; Keri J; Woolery-Lloyd HC; Harper JC; Cook-Bolden FE; Konda A; Tanghetti EA
J Clin Aesthet Dermatol; 2023 Sep; 16(9):42-45. PubMed ID: 37720201
[TBL] [Abstract][Full Text] [Related]
37. Fixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%-5% Affected Body Surface Area.
Tanghetti EA; Bhatia N; Drew S; Jacobson A
J Drugs Dermatol; 2021 Aug; 20(8):829-836. PubMed ID: 34397206
[TBL] [Abstract][Full Text] [Related]
38. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris.
Tanghetti E; Dhawan S; Green L; Del Rosso J; Draelos Z; Leyden J; Shalita A; Glaser DA; Grimes P; Webster G; Barnett P; Le Gall N
J Drugs Dermatol; 2010 May; 9(5):549-58. PubMed ID: 20480800
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris.
Thiboutot D; Arsonnaud S; Soto P
J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s3-10. PubMed ID: 18575220
[TBL] [Abstract][Full Text] [Related]
40. In Vitro Rheology Predicts Improved Spreadability of Tazarotene 0.045% Lotion Versus Trifarotene 0.005% Cream.
Draelos Z; Tanghetti E; Werschler W; Kircik L; Angel A; Lagmay E; Guenin E
J Drugs Dermatol; 2022 Mar; 21(3):250-257. PubMed ID: 35254756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
